Prosensa Closes $30M C Round for Exon-Skipping Drug Pipeline

Prosensa Therapeutics BV raised €23 million (US$29.9 million) in a Series C round last week to enable it to move two new exon-skipping antisense oligonucleotide drugs into clinical development in Duchenne's muscular dystrophy (DMD) and to take forward preclinical programs in two other rare disease indications.